Skip to main content
. 2021 Mar 16;13(3):215. doi: 10.3390/toxins13030215

Figure 1.

Figure 1

The mean ± standard error (SE) of disease specific quality of life (HF30) with significant linear model (p = 0.004) and quadratic model (p = 0.002) (top left); the abnormal involuntary movement scale (AIMS) with significant linear model (p = 0.041) at second year and significant linear model (p = 0.009) at fourth year (top right); general health quality of life (SF-36) with significant linear model (p = 0.031) at fourth year after injections of Abo-BTX A (bottom left); and the mean ± standard error (SE) of the Center of Epidemiologic Studies-Depression (CES-D) questionnaire with no significant improvement after injections of Abo-BTX A (p = 0.924) (bottom right).